|Articles|April 1, 1999

April 1999
Volume 5
Issue 4

Discontinuation Rates of Cholesterol-Lowering Medications

Author(s)Janet G. Hiatt, PharmD, Stephanie G. Shamsie, PharmD, Gordon Schectman, MD

Download PDF: Discontinuation Rates of Cholesterol-Lowering Medications

Articles in this issue

over 27 years ago

Article

Medicaid Recipients' Experiences Under Mandatory Managed Care

over 27 years ago

Article

Why Primary Care Physicians Join HMOs

over 27 years ago

Article

The Role of Resource Allocation Models in Selecting Clinical Preventive Services

over 27 years ago

Article

Is Prior Authorization of Topical Tretinoin for Acne Cost Effective?

over 27 years ago

Article

Impact of Therapeutic Interchange from Pravastatin to Lovastatin in a Veterans Affairs Medical Center

over 27 years ago

Article

Targeted Intervention Programs: Creating a Customized Practice Model to Improve the Treatment of Allergic Rhinitis in a Managed Care Population

over 27 years ago

Article

Disease Management of Congestive Heart Failure

over 27 years ago

Article

Celecoxib: A COX-2 Inhibitor

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Discontinuation Rates of Cholesterol-Lowering Medications

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access